Eli Lilly and Co. said foreign-exchange pressures weighed on sales in the most recent quarter as the pharmaceutical company continued to suffer the impact of patent expirations on some of its key drugs.

Topics:  eli lilly   sales   patent expirations   
BING NEWS:
  • Analyst revamps Eli Lilly stock price target on weight loss drug
    The strength of Zepbound has led JPMorgan Chase analysts to lift their share price target for Lilly to $850 from $775. They left their rating unchanged at overweight. The stock recently traded at $764 ...
    03/18/2024 - 12:37 pm | View Link
  • GLP-1 surge, oncology stars to power industry's earnings growth over the next 18 months: Moody's
    The commercial frenzy of GLP-1 medicines from Eli Lilly and Novo Nordisk has not only resulted in skyrocketing revenue for both companies, it's also expected to be a major driving force behind the | ...
    03/15/2024 - 2:50 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News